Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RET | P07949 | 13/20 | 0.68 |
| ▸ | KDR | P35968 | 13/20 | 0.68 |
| ▸ | KIF5B | P33176 | 8/20 | 0.68 |
| ▸ | BRAF | P15056 | 3/20 | 0.62 |
| ▸ | RAF1 | P04049 | 2/20 | 0.62 |
| ▸ | EGFR | P00533 | 4/20 | 0.57 |
| ▸ | GAK | O14976 | 1/20 | 0.57 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.57 |
| ▸ | STK10 | O94804 | 1/20 | 0.57 |
| ▸ | FLT3 | P36888 | 1/20 | 0.57 |
| ▸ | JAK3 | P52333 | 1/20 | 0.57 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.57 |
| ▸ | Q6ZSR9 | Q6ZSR9 | 1/20 | 0.57 |
| ▸ | SLK | Q9H2G2 | 1/20 | 0.57 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.57 |
| ▸ | RPS6KA6 | Q9UK32 | 1/20 | 0.57 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.57 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.56 |
| ▸ | FLT1 | P17948 | 1/20 | 0.56 |
| ▸ | LCK | P06239 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6793966 | 0.91 | KDR (0.74) | RETKDRKIF5BEGFRRIPK2 | |
| SCHEMBL6675906 | 0.86 | KDR (0.73) | RETKDRKIF5BBRAFRAF1 | |
| SCHEMBL27782657 | 0.85 | RET (0.72) | RETKDRKIF5BEGFRGAK | |
| SCHEMBL5004836 | 0.82 | ABCG2 (0.64) | RETKDRKIF5BBRAFRAF1 | |
| SCHEMBL6674055 | 0.81 | KDR (0.82) | RETKDRKIF5BBRAFRAF1 | |
| SCHEMBL18158909 | 0.81 | RET (1.00) | RETKDRKIF5BBRAFRAF1 | |
| SCHEMBL14159636 | 0.81 | KDR (0.73) | RETKDRKIF5BEGFRGAK | |
| SCHEMBL20792806 | 0.79 | EGFR (0.87) | RETKDRKIF5BBRAFRAF1 | |
| SCHEMBL13604745 | 0.79 | EGFR (0.82) | RETKDRKIF5BBRAFRAF1 | |
| SCHEMBL7215803 | 0.78 | KDR (0.89) | RETKDRKIF5BBRAFRAF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080306096-A1 | Quinazoline Derivatives, Process for Their Preparation and Their Use as Anti-Cancer Agents | ASTRAZENECA AB (SE) | 2008-12-11 | — | — | US | disclosed |
| EP-1966159-A2 | CHEMICAL COMPOUNDS | AstraZeneca AB (SE) | 2008-09-10 | — | — | EP | disclosed |
| WO-2007071963-A2 | QUINAZOLINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS ANTI-CANCER AGENTS | ASTRAZENECA AB (SE) | 2007-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080306096-A1 | Quinazoline Derivatives, Process for Their Preparation and Their Use as Anti-Cancer Agents | BRAF, RAF1, NRAS | RET 469/4885KDR 1051/4885KIF5B 1393/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.